Last updated: 2026-09-07 20:52:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Skye Bioscience, Inc. (SKYE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.89, with a market capitalization of $8.24M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.64 to $39.92. This page covers its latest market performance, valuation, price trends and company information.
$8.24M | |
$1.77 | |
$29,000.00 | |
$1.64 | |
$1.78 | |
181.93K | |
71.08K | |
-- | |
$39.92 | |
$1.64 | |
-- | |
-- |
Skye Bioscience, Inc. (SKYE) last closed at $1.78 as of 2026-09-05 00:00:00, unchanged from the previous close of $1.78.
During the latest regular trading session, SKYE traded between $1.64 and $29,000.00, with a volume of 181.93K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Skye Bioscience, Inc. (SKYE) moved from $1.95 to $1.89, representing a decline of 3.23% ($0.06).
The stock traded between $1.64 and $2.05 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 84.84 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.6%
SKYE is currently trading at $1.89, placing it 0.6% of the way from its 52-week low of $1.64 to its 52-week high of $39.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Skye Bioscience, Inc. (SKYE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.